$-0.14 EPS Expected for OncoSec Medical Incorporated (ONCS)

May 17, 2018 - By Paula Hilliard

OncoSec Medical Incorporated (NASDAQ:ONCS) Logo

Analysts expect OncoSec Medical Incorporated (NASDAQ:ONCS) to report $-0.14 EPS on June, 7.They anticipate $0.08 EPS change or 36.36 % from last quarter’s $-0.22 EPS. After having $-0.24 EPS previously, OncoSec Medical Incorporated’s analysts see -41.67 % EPS growth. The stock decreased 7.30% or $0.13 during the last trading session, reaching $1.65. About 2.78 million shares traded or 136.22% up from the average. OncoSec Medical Incorporated (NASDAQ:ONCS) has risen 44.62% since May 18, 2017 and is uptrending. It has outperformed by 33.07% the S&P500.

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. The company has market cap of $84.95 million. The Company’s lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. It currently has negative earnings. ImmunoPulse is an electroporation delivery device used in combination with the companyÂ’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer.

Another recent and important OncoSec Medical Incorporated (NASDAQ:ONCS) news was published by Streetinsider.com which published an article titled: “Oncosec Medical (ONCS) Expands Relationship with Merck (MRK); Announces Clinical Collaboration to Evaluate …” on May 08, 2018.

OncoSec Medical Incorporated (NASDAQ:ONCS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.